Table 2.

Demographics and Clinical Profile of the Patients With Sarcoidosis and Summary of Their Post-transplant Course.

Patient profile	MELD	Bil	ALT	AP	Varices	EHS	Time to recurrence	Re-LT	Graft surv. (yrs.)	Patient surv. (yrs.)	Etiology of death
46 yr. old AAF	19	1.5	41	768	Yes	Lungs	–	No	7.70	7.70	–
43 yr. old AAF	20	6.8	75	515	Yes	Lungs/↑Ca	–	No	19.00	19.00	–
57 yr. old AAF	15	2.4	23	174	Yes	Lungs	–	No	7.90	7.90	–
49 yr. old AAM	19	10.4	102	297	Yes		222 days	No	4.60	4.60	Sepsis
47 yr. old CM	20	18.0	141	479	Yes	Lungs, skin and retina	–	No	9.00	9.00	Cardiac
30 yr. old AAF	13	11.0	95	1063	No	↑Ca	6.6 years	Yes	19.1	19.30	Sepsis
48 yr. old AAF	9	0.6	19	375	Yes	Lungs	–	No	11.20	11.20	–
40 yr. old AAF	12	13.8	138	192	Yes		–	No	20.30	20.30	–
42 yr. old AAMa	20	7.3	150	449	Yes	Lungs	112 days	Yes	3.7	4.10	Sepsis
47 yr. old AAMa	29	7.6	15	190	Yes	Lungs	–	No	0.40	4.10	Sepsis
32 yr. old AAM	17	12.0	172	331	Yes	Lungs	–	No	0.11	0.11	Sepsis
61 yr. old CF	23	14.0	31	222	Yes	Lungs	–	No	9.70	9.70	–
40 yr. old AAF	16	10.2	121	778	No		–	Yes	1.7	1.90	Sepsis (mycotic aneurysm)
55 yr. old AAMa	22	3.5	23	85	Yes	Lungs	11 days	Yes	0.05	0.05	Respiratory failure

ReLT, re-transplant; Bil, bilirubin; MELD, Model for End Stage Liver Disease score; AAF, African American female; AAM, African American male; CM, Caucasian male; CF, Caucasian female; EHS, extra hepatic sarcoidosis.

* Explant pathology in all patients showed features of granulomatous hepatitis and cirrhosis of the liver.

^aConcomitant HCV infection.